Evaluation of CD45 antigen expression in patients with multiple myeloma and its effect on time to progression or relapse

Czech version

Authors: A. Jungová ¹; M. Holubová ¹; S. Vokurka ¹; D. Lysák ¹; P. Jindra ¹; P. Dvořák ²
Authors‘ workplace: Hematologicko-onkologické odd., Fakultní nemocnice v Plzni ¹; Ústav lékařské genetiky, Fakultní nemocnice v Plzni ²
Published in: Transfuze Hematol. dnes,20, 2014, No. 2, p. 53-57.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Multiple myeloma is one of the most common haematological diseases of variable course ranging from aggressive to indolent chronic forms. Prognostic stratification is based on cytogenetics as well as newer methodologies including flow cytometry. The CD45 antigen could be one prognostic factor which could specify disease risk of at diagnosis. 71 patients in our study sample were divided according to the intensity of CD45 expression and the group with lower CD45 expression had significantly higher risk of relapse within 12 months 62% vs. 25 % (p = 0.0011). There was no significant difference in the demographic parameters (age, sex), 1st line treatment with autologous transplantation and complete remissions after 1st line treatment or cytogenetic findings. We believe that CD45 expression could become one of the prognostic factors or one of the factors that determine the need for maintenance therapy in patients with multiple myeloma. We recommend that these results be confirmed on a larger sample or within a multi-centre study.

Key words:
multiple myeloma, plasmocytes, flow cytometry, cytogenetics, CD45, time to progression (TTP)

Sources

1. Raab MS, Podar K, Breitkreutz I, Tichardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 9686: 324-339.

2. Kovářová L, Hájek R. Flowcytometrická analýza plazmatických buněk u mnohočetného myelomu. Klinická onkologie 2008; 21: 249-252.

3. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigen expression in multiple myeloma. Clin Cancer Res 2005; 11(10): 3661-3667.

4. Ajaz B, Akhtar A, Chang CC, Solh M, Tangonan K, Khaled Y. Plasma cell CD20 expression: Primary aberrant expression or receptor up regulativ. Leuk Lymphoma 2014; 55(2): 444-446.

5. Elleder M. Buněčné klony – fyziologie a patologie. ÚDMP-1. LFUK 2009. http://www1.lf1.cuni.cz/udmp/web2/klony/klony.pdf.

6. Dews M, Nishimoto I, Baserga R. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Recept Signal Transduct 1997; 7(4): 231-240.

7. Moreau P, Robillard N, Avet-Loiseau H, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89(5): 547-551.

8. Czech Myeloma Group. Mnohočetný myelom, diagnostické testy, doporučené postupy léčby. Transfuze Hematol dnes 2009; 15: 5-80.

9. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495.

10. Kim H, Hee-Jung S, Shin K, et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantion as first-line therapy. Biol Blood Marrow Transplant 2006; 12(8): 837-844.

11. Kumar S, Kimlinger T, Morice W. Imunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol 2010; 23(3): 433-451.

12. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005; 19(8): 1466-1470.

13. Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004; 32: 293-301.

14. Collette M, Descamps G, Pellat-Deceunynck C, Bataille R, Amiot M. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw 2007; 18(3): 120-126.

15. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25 (7): 799-804.